| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US9585906 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(5 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(5 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(5 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US9868745 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957046 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(7 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
| US11338007 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
|
US11338007 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Dec, 2037
(14 years from now) | |
Vosevi is owned by Gilead Sciences Inc.
Vosevi contains Sofosbuvir; Velpatasvir; Voxilaprevir.
Vosevi has a total of 33 drug patents out of which 0 drug patents have expired.
Vosevi was authorised for market use on 18 July, 2017.
Vosevi is available in tablet;oral dosage forms.
Vosevi can be used as treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor, treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor.
Drug patent challenges can be filed against Vosevi from 2021-07-18.
The generics of Vosevi are possible to be released after 01 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 2021-07-18
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...
Dosage: TABLET;ORAL
VOSEVI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic